ANIX - ITUS (Anixa Biosciences Inc.)

ANIXのニュース

   Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference  2022/05/05 12:30:00 PR Newswire
SAN JOSE, Calif., May 5, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright Global Investment…
   48 Stocks Moving In Friday''s Mid-Day Session  2022/04/29 16:27:16 Benzinga
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE ) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ: GTYH ) shares jumped 116.3% to $6.12 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX ) surged 63.3% to $6.17. Vaxxinity Executive chairman Lou Reese purchased 22,912 shares at $3.48 per share. Zymeworks Inc. (NYSE: ZYME ) shares climbed 32% to $6.55. Zymeworks confirmed it received an unsolicited, non-binding proposal from All Blue Falcons FZE and its affiliates to purchase the company for $10.50 per share. The Zymeworks board of directors will carefully review the proposal. Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) gained 29.5% to $2.72. The FDA has removed the clinical hold on Finch Therapeutics Group’s investigational new drug application for CP101, an orally administered microbiome therapeutic, which is in Phase 3 study for recurrent C. difficile infection. Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) jumped 29.2% to $23.79.
   Anixa Biosciences initiates phase 1 trial of its ovarian cancer CAR-T therapy  2022/03/30 18:30:12 Seeking Alpha
Biotechnology company Anixa Biosciences <> initiated a phase 1 trial evaluating its CAR-T therapy in ovarian cancer.The early-stage trial will be held at Moffitt Cancer Center…
   Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center  2022/03/30 16:45:00 PR Newswire
SAN JOSE, Calif., March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor…
   Anixa says new protease inhibitor outperformed main agent in Pfizer’s COVID-19 pill  2022/01/24 14:06:25 Seeking Alpha
Anixa Biosciences (ANIX) has added ~6.5% in the pre-market after announcing that in early lab studies, a molecule developed by the company and partner MolGenie GmbH was more potent…
   Such Is The Power Of Anixa Biosciences Inc. (NASDAQ: ANIX)  2021/12/08 13:00:00 Stocks Register
Anixa Biosciences Inc. (NASDAQ:ANIX) price closed higher on Tuesday, December 07, jumping 3.35% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy
   Anixa Biosciences Says COVID-19 Compounds Potentially Effective Against Omicron Variant  2021/12/07 17:41:42 Benzinga
Anixa Biosciences Inc (NASDAQ: ANIX ) announced the results of a genomic variant analysis conducted with its partner, MolGenie GmbH , on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant, in addition to the previously identified Delta variant Full story available on Benzinga.com
   Anixa Biosciences Inc. (NASDAQ: ANIX): The Stock For Success Over The Next Few Months  2021/12/07 17:00:00 Marketing Sentinel
In the latest trading session, 0.84 million Anixa Biosciences Inc. (NASDAQ:ANIX) shares changed hands as the companys beta touched 1.75. With the companys most recent per share price at $3.37 changing hands around $0.24 or 7.67% at last look, the market valuation stands at $97.66M. ANIXs current price is a discount, trading about -140.06% off Anixa Biosciences Inc. (NASDAQ: ANIX): The Stock For Success Over The Next Few Months Read More »
   Brokerages Expect Anixa Biosciences, Inc. (NASDAQ:ANIX) Will Announce Earnings of -$0.09 Per Share  2021/12/04 16:36:42 Dakota Financial News
Brokerages expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to announce earnings per share of ($0.09) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Anixa Biosciences earnings. Anixa Biosciences reported earnings per share of ($0.81) in the same quarter last year, which suggests a positive year-over-year growth rate of 88.9%. The business []
   Zacks: Brokerages Expect Anixa Biosciences, Inc. (NASDAQ:ANIX) Will Announce Earnings of -$0.09 Per Share  2021/12/02 11:12:43 Transcript Daily
Wall Street brokerages expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to report earnings of ($0.09) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Anixa Biosciences earnings. Anixa Biosciences reported earnings per share of ($0.81) in the same quarter last year, which would suggest a positive year over year growth rate []
   Anixa Biosciences gets notice of allowance for additional patent on its CAR-T cancer therapy  2021/10/01 12:36:09 Seeking Alpha
   Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy  2021/10/01 12:30:00 PR Newswire
SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of
   Our First Look At Anixa Biosciences  2021/09/23 16:00:27 Seeking Alpha
   Cancer Vaccines Market 2021 Research, Growth and Clinical Analysis - ADAMIS PHARMACEUTICALS CORP., ADVAXIS INC., ALPHAVAX INC., AMGEN INC., Anixa Biosciences Inc  2021/09/08 10:31:11 OpenPR
The report presents an in-depth assessment of the Cancer Vaccines Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also
   Anixa Biosciences Says FDA Clears IND For CAR-T Immunotherapy For Ovarian Cancer - Quick Facts  2021/08/30 12:54:50 Business Insider Markets
(RTTNews) - Biotechnology company Anixa Biosciences, Inc. (ANIX) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center. The therapeutic product is

calendar